Graft-versus-host	graft-versus-host	O	O	O	O
disease	disease	O	O	O	O
prophylaxis	prophylaxis	O	O	O	O
with	with	O	O	O	O
everolimus	everolimus	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
high	high	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
sinusoidal	sinusoidal	O	O	OTHERS	I
obstruction	obstruction	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
and	and	O	O	O	O
microangiopathy	microangiopathy	O	O	OTHERS	I
:	:	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
EVTAC	evtac	O	O	O	O
trial	trial	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
calcineurin	calcineurin	O	O	O	O
inhibitor	inhibitor	O	O	O	O
combined	combined	O	O	O	O
with	with	O	O	O	O
methotrexate	methotrexate	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
the	the	O	O	O	O
standard	standard	O	O	O	O
prophylaxis	prophylaxis	O	O	O	O
for	for	O	O	O	O
graft-versus-host	graft-versus-host	O	O	O	O
disease	disease	O	O	O	O
(	(	O	O	O	O
GVHD	gvhd	O	O	OTHERS	I
)	)	O	O	O	O
after	after	O	O	O	O
allogeneic	allogeneic	O	O	O	O
hematopoietic	hematopoietic	O	O	O	O
stem	stem	O	O	O	O
cell	cell	O	O	O	O
transplantation	transplantation	O	O	O	O
(	(	O	O	O	O
HSCT	hsct	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Everolimus	everolimus	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
derivative	derivative	O	O	O	O
of	of	O	O	O	O
sirolimus	sirolimus	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
seems	seems	O	O	O	O
to	to	O	O	O	O
mediate	mediate	O	O	O	O
antileukemia	antileukemia	O	O	O	O
effects	effects	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
on	on	O	O	O	O
a	a	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
everolimus	everolimus	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
tacrolimus	tacrolimus	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
24	24	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
median	median	O	O	O	O
age	age	O	O	O	O
,	,	O	O	O	O
62	62	O	O	O	O
years	years	O	O	O	O
)	)	O	O	O	O
with	with	O	O	O	O
either	either	O	O	O	O
myelodysplastic	myelodysplastic	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
(	(	O	O	O	O
MDS	mds	O	O	OTHERS	I
;	;	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
17	17	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
acute	acute	O	O	OTHERS	I
myeloid	myeloid	O	O	OTHERS	I
leukemia	leukemia	O	O	OTHERS	I
(	(	O	O	O	O
AML	aml	O	O	OTHERS	I
;	;	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
7	7	O	O	O	O
)	)	O	O	O	O
undergoing	undergoing	O	O	O	O
intensive	intensive	O	O	O	O
conditioning	conditioning	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
HSCT	hsct	O	O	O	O
from	from	O	O	O	O
related	related	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
4	4	O	O	O	O
)	)	O	O	O	O
or	or	O	O	O	O
unrelated	unrelated	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
20	20	O	O	O	O
)	)	O	O	O	O
donors	donors	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
engrafted	engrafted	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
only	only	O	O	O	O
1	1	O	O	O	O
patient	patient	O	O	O	O
experienced	experienced	O	O	O	O
grade	grade	O	O	O	O
IV	iv	O	O	O	O
mucositis	mucositis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Nine	nine	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
37	37	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
acute	acute	O	O	O	O
grade	grade	O	O	O	O
II-IV	ii-iv	O	O	O	O
GVHD	gvhd	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
11	11	O	O	O	O
of	of	O	O	O	O
17	17	O	O	O	O
evaluable	evaluable	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
64	64	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
chronic	chronic	O	O	O	O
extensive	extensive	O	O	O	O
GVHD	gvhd	O	O	OTHERS	I
.	.	O	O	O	O

Transplantation-associated	transplantation-associated	O	O	O	O
microangiopathy	microangiopathy	O	O	OTHERS	I
(	(	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
)	)	O	O	O	O
occurred	occurred	O	O	O	O
in	in	O	O	O	O
7	7	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
29	29	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
2	2	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
acute	acute	O	DISEASE	OTHERS	I
renal	renal	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
terminated	terminated	O	O	O	O
prematurely	prematurely	O	O	O	O
because	because	O	O	O	O
an	an	O	O	O	O
additional	additional	O	O	O	O
6	6	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
25	25	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
developed	developed	O	O	O	O
sinusoidal	sinusoidal	O	O	OTHERS	I
obstruction	obstruction	O	O	OTHERS	I
syndrome	syndrome	O	O	OTHERS	I
(	(	O	O	O	O
SOS	sos	O	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
which	which	O	O	O	O
was	was	O	O	O	O
fatal	fatal	O	O	O	O
in	in	O	O	O	O
2	2	O	O	O	O
cases	cases	O	O	O	O
.	.	O	O	O	O

With	with	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
26	26	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
2-year	2-year	O	O	O	O
overall	overall	O	O	O	O
survival	survival	O	O	O	O
rate	rate	O	O	O	O
was	was	O	O	O	O
47	47	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
this	this	O	O	O	O
new	new	O	O	O	O
combination	combination	O	O	O	O
appears	appears	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
effective	effective	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
prophylactic	prophylactic	O	O	O	O
regimen	regimen	O	O	O	O
for	for	O	O	O	O
acute	acute	O	O	O	O
GVHD	gvhd	O	O	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
TMA	tma	O	DISEASE	OTHERS	I
and	and	O	O	O	O
SOS	sos	O	O	OTHERS	I
is	is	O	O	O	O
considerably	considerably	O	O	O	O
higher	higher	O	O	O	O
than	than	O	O	O	O
seen	seen	O	O	O	O
with	with	O	O	O	O
other	other	O	O	O	O
regimens	regimens	O	O	O	O
.	.	O	O	O	O

